Miguel-angel A. Perales

Hematology | Oncology

530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 458 publications

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Journal: JAMA oncology

Published: June 18, 2026

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas.

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas.

Journal: Transplantation and cellular therapy

Published: April 24, 2026

Tuberculosis After Allogeneic Hematopoietic Cell Transplant: A 15-Year Case Series Highlighting Diagnostic Challenges.

Tuberculosis After Allogeneic Hematopoietic Cell Transplant: A 15-Year Case Series Highlighting Diagnostic Challenges.

Journal: Transplantation and cellular therapy

Published: April 15, 2026

Tuberculosis After Allogeneic Hematopoietic Cell Transplant: A 15-Year Case Series Highlighting Diagnostic Challenges.

Tuberculosis After Allogeneic Hematopoietic Cell Transplant: A 15-Year Case Series Highlighting Diagnostic Challenges.

Journal: Transplantation and cellular therapy

Published: April 15, 2026

The 2026 definition of ruxolitinib refractoriness in severe acute GVHD.

The 2026 definition of ruxolitinib refractoriness in severe acute GVHD.

Journal: Bone marrow transplantation

Published: April 03, 2026

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Journal: Transplantation and cellular therapy

Published: April 03, 2026

Correction: Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease.

Correction: Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease.

Journal: Bone marrow transplantation

Published: March 30, 2026

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: March 13, 2026

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Journal: Transplantation and cellular therapy

Published: March 04, 2026

Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignancies.

Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignancies.

Journal: Transplantation and cellular therapy

Published: March 04, 2026

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.

Journal: bioRxiv : the preprint server for biology

Published: February 27, 2026

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

Journal: The Lancet. Haematology

Published: February 03, 2026

Showing 1-12 of 458

Last Updated: 09/26/2026